Cofetuzumab Pelidotin

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCofetuzumab Pelidotin
Drug Alias NameHumanized 6M024Anti-PTK7 ADCHumanized 6M24PTK7-ADCPF-06523435 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Aur0101 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin inhibitorsAnti-PTK7Wnt signalling pathway modulators
TargetsTubulinProtein-tyrosine kinase 7
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanIsrael +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie IncStemcentrx Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesPfizer Inc
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A